# PD_Lab_book


## Objective 1
###### Learning cell culture basics
###### SRB cytotoxicity assays with crizotinib
Aim: 3 or more consistent concentration/cell viability curves<br>
[Results](Objective_summaries/Crizotinib_cytotoxicity_assays.md)

## Objective 2
###### SRB cytotoxicity assay with selumetinib (MEK inhibitor)
Concentrations via Nensi<br>
Aim: 3 or more consistent concentration/cell viability curves<br>
[Results](Objective_summaries/Selumetinib_cytotoxicity_assays.md)

## Objective 3
###### SRB cytotoxicity assay with crizotinib and selumetinib
Concentrations will depend of crizotinib and selumetinib IC50 values<br>
Aim: 3 or more consistent concentration/cell viability curves and learn combination drug data analysis

## Objective 4
###### SRB cytotoxicity assay with ABT-737
Aim: 3 or more consistent concentration/cell viability curves

## Objective 5
###### SRB cytotoxicity assay with ABT-737 and crizotinib<br>
Aim: 3 or more consistent concentration/cell viability curves

## Objective 6
###### SRB cytotoxicity assay with ABT-737, crizotinib and selumetinib<br>
Aim: 3 or more consistent concentration/cell viability curves<br>

## Objective 7
###### H3122 and CR-H3122 kinase domain sequencing
Aim: Amplify the ALK kinase domain from both H3122 and CR-H3122 and use Sanger sequencing to identify any crizotinib resistance mutations in CR-H3122. <br>
[Summary](../Objective_summaries/CR-H3122_Sequencing.md)
